Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to carrying a high risk of bowel cancer, also greatly increases the risk of duodenal cancer. At present, the only ...

Use of the epidermal growth-factor receptor inhibitor erlotinib led to about a 30% reduction in duodenal polyp burden after 6 months of once-weekly treatment for patients with familial adenomatous ...

The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis are ...

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP ...

Parabilis Medicines (PBLS) has initiated a dose-ranging group to evaluate its investigational drug zolucatetide in patients with familial adenomatous polyposis as part of an ongoing phase 1/2 trial, ...

Undergoing cancer treatment at a younger age can put the survivors at risk of developing numerous gastrointestinal polyps, even if they do not have hereditary susceptibility to polyposis. The acquired ...

Parabilis Medicines launched a zolucatetide dose-ranging cohort in familial adenomatous polyposis after early polyp ...